Wick KR, Berton MT (2000) IL-4 induces serine phosphorylation of the STAT6 transactivation domain in B lymphocytes. Mol Immunol 37, 641-52 11164892

This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2015, 43:D512-20). To learn more about the scope of PhosphoSitePlus®, click here.

Click on the protein name to open the protein page, and on the RSD number to open the site page.

Download

Y641-p - STAT6 (mouse) ▲

Modsite: MGKDGRGyVSTtIKM SwissProt Entrez-Gene Orthologous residues STAT6 (human): Y641‑p, STAT6 iso2 (human): Y467‑p, STAT6 (mouse): Y641‑p, STAT6 (rat): Y641‑p Characterization Methods used to characterize site in vivo:  [32P] bio-synthetic labeling, mutation of modification site, phosphoamino acid analysis, phosphopeptide mapping Disease tissue studied:  lymphoma, B cell lymphoma Relevant cell lines - cell types - tissues:  293 (epithelial), B lymphocyte-spleen Cellular systems studied:  cell lines, primary cells Species studied:  human, mouse Comments:  BCL1-3B3 cells (lymphoma cell line) Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes IL-4 increase wortmannin IL-4 no effect upon treatment-induced increase LY294002 IL-4 no effect upon treatment-induced increase H-7 IL-4 no effect upon treatment-induced increase HA-1004 IL-4 no effect upon treatment-induced increase